Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency

Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency

Abstract T-cell immunity is central for control of COVID-19, particularly in patients incapable of mounting antibody responses. CoVac-1 is a peptide-based T-cell activator composed of SARS-CoV-2 epitopes with documented favorable safety profile and efficacy in terms of SARS-CoV-2-specific T-cell res...

Full description

Bibliographic Details
Main Authors: Jonas S. Heitmann, Claudia Tandler, Maddalena Marconato, Annika Nelde, Timorshah Habibzada, Susanne M. Rittig, Christian M. Tegeler, Yacine Maringer, Simon U. Jaeger, Monika Denk, Marion Richter, Melek T. Oezbek, Karl-Heinz Wiesmüller, Jens Bauer, Jonas Rieth, Marcel Wacker, Sarah M. Schroeder, Naomi Hoenisch Gravel, Jonas Scheid, Melanie Märklin, Annika Henrich, Boris Klimovich, Kim L. Clar, Martina Lutz, Samuel Holzmayer, Sebastian Hörber, Andreas Peter, Christoph Meisner, Imma Fischer, Markus W. Löffler, Caroline Anna Peuker, Stefan Habringer, Thorsten O. Goetze, Elke Jäger, Hans-Georg Rammensee, Helmut R. Salih, Juliane S. Walz
Format: Article
Language:English
Published: Nature Portfolio 2023-08-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-023-40758-0

Internet

https://doi.org/10.1038/s41467-023-40758-0

Similar Items